Key study of Grail’s cancer detection test fails in setback for company
statnews.com • • business
Key Points:
- Grail's blood test for early cancer detection failed to meet its primary goal in a large study conducted with England’s National Health Service.
- The test, called Galleri, aims to detect multiple cancer types early and suggest tumor locations, but it is not yet FDA-approved.
- Despite the setback, Grail sold 185,000 Galleri tests in 2025, generating $136.8 million in revenue.
- Following the announcement, Grail's shares dropped 47% in after-hours trading.
